Mechanisms in Cancer Evolution Program (MCEP) PROJECT SUMMARY The mission of the Mechanisms in Cancer Evolution Program (MCEP) at the DLDCCC is focused on understanding molecular mechanisms that generate heterogeneity (genetic and non-genetic or epi-genetic) and environmental drivers that spur evolution of cancers. Evolution occurs by variation, which creates heterogeneity and selection. Heterogeneity is generated by intrinsic genomic and non-genetic phenotype-plasticity mechanisms, as well as by alteration of cellular programs by extrinsic viruses, the microbiome, and nutritional modulation. The goal of the MCEP is fundamental basic science discovery of how these molecular mechanisms work. New paradigms discovered can open new translational directions (throughout the DLDCCC Programs and by others), including novel evolutionary biomarkers, diagnostic, preventative, and therapeutic tools. For example, whereas conventional therapies kill cells or stop them from growing (are anti-proliferative), proposed novel interventions that would slow evolution, promise new and fundamentally different ways to inhibit oncogenesis and thwart resistance. Also, identification of biomarkers of highly evolvable cells may allow detection of at-risk individuals, and earlier detection of cancers. The MCEP currently has 26 members: 25 are Research members from the BCM Departments of Molecular and Human Genetics, Molecular Virology and Microbiology, Biochemistry and Molecular Biology, Pediatrics-Oncology, Medicine-Infectious Disease, Pathology and Immunology, and the Huffington Center on Aging; one is an adjunct member, appointed at the University of Texas, Austin. Members of the MCEP published a total of 576 cancer-related papers in the previous funding period with 25% in journals with Impact Factors of 10 or above. Of the 576 manuscripts, 11% represented intra- programmatic, 46% inter-programmatic, and 68% inter-institutional collaborations. The MCEP currently has a total of $10.5 million in selected cancer-relevant funding (direct costs per annum), which includes $2 million from NCI, $5.8 million in other NIH funding and $2.2 million in other peer reviewed funding mostly from the Cancer Prevention and Research Initiative of Texas (CPRIT). The two MCEP Aims encompass mechanisms of promotion of heterogeneity by: (1) Intrinsic Evolution Promoters (mutation, genome rearrangement, recombination, epigenetic heritable protein- and RNA-error-mediated variation); and (2) Extrinsic Evolution Promoters, including viruses, microbes generally, the microbiome, and nutritional modulators of both host and microbiome. The CCSG supports this Research Program by providing key Shared Resources, particularly High- Parameter Flow Cytometry; Advanced Microscopy and Image Informatics; Genomic, Transcriptomic, Epigenomic and Single-Cell, Metabolomics, and Proteomics; as well as administrative support for meetings, clubs and interest groups, and pilot funding and recruitment funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-14
Application #
10025019
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2007-07-01
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Nair, Amritha; Chung, Hsiang-Ching; Sun, Tingting et al. (2018) Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med 24:505-511
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Singh, Ramesh; Karri, Dileep; Shen, Hong et al. (2018) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest 128:3129-3143
Berntsson, Shala G; Merrell, Ryan T; Amirian, E Susan et al. (2018) Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. J Neurol 265:1432-1442
Chen, Fengju; Zhang, Yiqun; Gibbons, Don L et al. (2018) Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res 24:2182-2193
Maldonado, Maria; Molfese, David L; Viswanath, Humsini et al. (2018) The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. J Cachexia Sarcopenia Muscle 9:497-504
Richards, JoAnne S; Ren, Yi A; Candelaria, Nicholes et al. (2018) Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update. Endocr Rev 39:1-20
Kogiso, Mari; Qi, Lin; Braun, Frank K et al. (2018) Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin Cancer Res 24:2159-2170
Takahashi, Hannah; Cornish, Alex J; Sud, Amit et al. (2018) Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Sci Rep 8:2339

Showing the most recent 10 out of 991 publications